Gilead and Lakefront Complete $1.675 Billion Ouro Medicines Acquisition

Gilead Sciences (Nasdaq: GILD) and Lakefront Biotherapeutics (Euronext and Nasdaq: LKFT) completed the acquisition of Ouro Medicines on June 4, 2026, with Gilead paying $1,675 million for all outstanding equity plus up to $500 million in contingent milestone payments, per the company's announcement. The deal adds gamgertamig (OM336), a clinical-stage BCMAxCD3 T-cell engager, to Gilead's inflammation portfolio.

What does the asset actually do?

Gamgertamig is designed to enable rapid and deep plasma cell and B cell depletion following a limited subcutaneously administered treatment course, with the potential to induce durable disease control in severe antibody-mediated diseases including autoimmune hemolytic anemia and immune thrombocytopenia, per the announcement. The molecule has been granted both Fast Track and Orphan Drug designation by the FDA for AIHA and ITP, and is expected to enter registrational studies as early as 2027, per the company. Those designations are formal regulatory statuses; potential and expected are the company's words, not demonstrated outcomes.

Why split the payment with Lakefront?

The structure is the original angle of the deal. Gilead and Lakefront equally split both the upfront payment and the contingent milestones of up to $500 million, per the announcement. Lakefront takes responsibility for ongoing and future Phase 1/2 clinical studies of gamgertamig, Gilead leads registrational and later-stage studies, and Gilead retains sole worldwide commercialization rights outside of Keymed's territories. Lakefront receives tiered royalties of 20 to 23 percent on net sales from Gilead.

The cost-sharing design drew analyst attention when the acquisition was first agreed in March 2026. As BioSpace reported, the Ouro purchase continued a run of Gilead dealmaking that included the $7.8 billion acquisition of CAR-T developer Arcellx the previous month, part of what CEO Daniel O'Day called the pharma's proactive and disciplined business-development strategy.

What happens next on the calendar?

The registrational program. The company's stated expectation is studies as early as 2027, which sets the clinical-readout horizon beyond that. The remaining contingent payments of up to $500 million are tied to milestones the announcement does not individually itemize, and Lakefront has also in-licensed a preclinical portfolio of three additional autoimmune-focused programs from the transaction, per the completion release, with terms not itemized. For Lakefront shareholders, the transaction converts a development-stage cost base into a co-funded program backed by Gilead’s balance sheet.

For the T-cell engager field, the completed deal is another inflamation-focused exit for a modality whose center of gravity has shifted from oncology toward autoimmune disease. The dollar figure makes Gilead's commitment concrete; whether gamgertamig works in registrational testing is a question the studies, not the press release, will answer.